Page last updated: 2024-12-09

1,6-anhydro-3,4-dideoxy-beta-d-glycero-hex-3-enopyran-2-ulose

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1,6-anhydro-3,4-dideoxy-β-D-glycero-hex-3-enopyran-2-ulose, often referred to as **D-glucal**, is a carbohydrate derivative with a unique structure that makes it crucial for several research areas. Here's a breakdown:

**Structure and Characteristics:**

* **Anhydro:** This indicates a ring structure with an oxygen bridge between positions 1 and 6.
* **Dideoxy:** It's missing two hydroxyl groups (oxygen and hydrogen) at positions 3 and 4.
* **β-D-glycero-hex-3-enopyran:** This describes the sugar's configuration – a six-membered pyranose ring (hex) with a double bond at position 3, belonging to the D-glycero series, and in the β-anomeric form.
* **2-ulose:** It has a ketone functional group at position 2.

**Importance in Research:**

**1. Chemical Synthesis:**

* **Building Block:** D-glucal serves as a versatile starting material for synthesizing various complex carbohydrate structures, including glycosides, oligosaccharides, and even natural product analogs. Its reactivity with various reagents and its ability to undergo ring-opening reactions make it ideal for building diverse sugar structures.

**2. Bioconjugation and Drug Delivery:**

* **Linker:** The double bond in D-glucal allows it to be easily conjugated to various molecules like proteins, peptides, or drugs. This creates drug conjugates with improved properties, such as increased stability, targeted delivery, and enhanced biological activity.

**3. Carbohydrate Mimics and Inhibitors:**

* **Enzyme Probes:** The unique structure of D-glucal makes it a valuable tool for studying carbohydrate-binding enzymes. It can be used as a substrate mimic or inhibitor to understand the mechanisms of enzyme activity and develop new drugs.

**4. Materials Science:**

* **Self-Assembly:** D-glucal can form supramolecular assemblies due to its ability to hydrogen bond and interact with other molecules. This property is being explored for applications in materials science, such as creating new polymers and nanomaterials.

**5. Biology and Glycobiology:**

* **Glycosylation Studies:** D-glucal analogs can be incorporated into glycans, which are complex sugar structures found on proteins and lipids. This allows researchers to investigate the role of glycosylation in biological processes and disease.

**In summary, 1,6-anhydro-3,4-dideoxy-β-D-glycero-hex-3-enopyran-2-ulose (D-glucal) is a valuable tool in various research fields due to its unique structural features, reactivity, and ability to be modified. Its applications range from chemical synthesis and drug development to materials science and biological studies.**

1,6-anhydro-3,4-dideoxyhex-3-enopyran-2-ulose: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID699486
CHEMBL ID4126941
CHEBI ID30999
SCHEMBL ID7155405
MeSH IDM0501086

Synonyms (36)

Synonym
6,8-dioxabicyclo(3.2.1)oct-2-en-4-one, (1s)-
brn 4859778
ccris 4274
37112-31-5
CHEBI:30999
(1s)-6,8-dioxabicyclo(3.2.1)oct-2-en-4-one
levoglucosenone
(1s,5r)-6,8-dioxabicyclo[3.2.1]oct-2-en-4-one
1,6-anhydro-3,4-dideoxy-beta-d-glycero-hex-3-enopyranos-2-ulose
(1s)-6,8-dioxabicyclo[3.2.1]oct-2-en-4-one
AKOS006345460
1,6-anhydro-3,4-dideoxyhex-3-enopyran-2-ulose
b7n23sn1lb ,
unii-b7n23sn1lb
1,6-anhydro-3,4-dideoxy-beta-d-glycero-hex-3-enopyran-2-ulose
SCHEMBL7155405
L0150
HITOXZPZGPXYHY-UJURSFKZSA-N
PS-4213
W-202534
levoglucosenone [mi]
1,6-anhydro-3,4-dideoxy-.beta.-d-glycero-hex-3-enopyranos-2-ulose
levoglucosenone, (-)-
6,8-dioxabicyclo(3.2.1)oct-2-en-4-one, (1s,5r)-
1,6-anhydro-3,4-dideoxy-.delta.3-.beta.-d-pyranosen-2-one
levoglucosenone, >=95% (gc)
BCP07825
Q27114054
chembl4126941 ,
bdbm50276378
BB 0322953
T72379
A856725
6,8-dioxabicyclo3.2.1oct-2-en-4-one, (1s,5r)-
CS-0016272
HY-21226
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
anhydrohexoseAny anhydro sugar formally arising by elimination of water from two hydroxy groups of a single molecule of a hexose or hexose derivative.
deoxyketohexoseAny ketohexose having at least one hydroxy group replaced by hydrogen.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
NACHT, LRR and PYD domains-containing protein 3 Mus musculus (house mouse)IC50 (µMol)1.20000.00041.441910.0000AID1498932
NACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)IC50 (µMol)6.60000.00502.180410.0000AID1498934
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (28)

Processvia Protein(s)Taxonomy
pattern recognition receptor signaling pathwayNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
negative regulation of acute inflammatory responseNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
positive regulation of type 2 immune responseNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
apoptotic processNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
defense responseNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
inflammatory responseNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
signal transductionNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
osmosensory signaling pathwayNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
detection of biotic stimulusNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
negative regulation of interleukin-1 beta productionNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
positive regulation of interleukin-1 beta productionNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
positive regulation of interleukin-4 productionNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
NLRP3 inflammasome complex assemblyNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
innate immune responseNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
positive regulation of T-helper 2 cell differentiationNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
negative regulation of inflammatory responseNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
positive regulation of inflammatory responseNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
protein homooligomerizationNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
protein maturationNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
pyroptosisNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
cellular response to lipopolysaccharideNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
cellular response to virusNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
negative regulation of non-canonical NF-kappaB signal transductionNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
positive regulation of T-helper 2 cell cytokine productionNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (16)

Processvia Protein(s)Taxonomy
protein bindingNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
ATP bindingNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
ATP hydrolysis activityNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
protein-macromolecule adaptor activityNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
signaling adaptor activityNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
identical protein bindingNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
peptidoglycan bindingNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
ADP bindingNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
sequence-specific DNA bindingNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
molecular adaptor activityNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
phosphatidylinositol-4-phosphate bindingNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
DNA-binding transcription factor bindingNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
small molecule sensor activityNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
cysteine-type endopeptidase activator activityNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
molecular condensate scaffold activityNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
phosphatidylinositol phosphate bindingNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
cytosolNACHT, LRR and PYD domains-containing protein 3 Mus musculus (house mouse)
cytoplasmNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
cytosolNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
membraneNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
Golgi membraneNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
extracellular regionNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
nucleusNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
cytoplasmNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
mitochondrionNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
endoplasmic reticulumNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
microtubule organizing centerNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
cytosolNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
interphase microtubule organizing centerNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
NLRP3 inflammasome complexNACHT, LRR and PYD domains-containing protein 3 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1498932Inhibition of nigericin-induced NLRP3 inflammasome activation in C57BL/6 mouse bone marrow derived macrophages assessed as reduction in LPS-stimulated IL-1beta secretion incubated for 1 hr followed by nigericin addition measured after 1 hr by ELISA2018Bioorganic & medicinal chemistry, 07-30, Volume: 26, Issue:13
Synthesis of 1,5-Anhydro-d-fructose derivatives and evaluation of their inflammasome inhibitors.
AID1636613Cytotoxicity against human HuH7 cells assessed as reduction in cell growth after 48 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Cytotoxic effect of levoglucosenone and related derivatives against human hepatocarcinoma cell lines.
AID1636614Cytotoxicity against human HepG2 cells assessed as reduction in cell growth after 48 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Cytotoxic effect of levoglucosenone and related derivatives against human hepatocarcinoma cell lines.
AID1498934Inhibition of nigericin-induced NLRP3 inflammasome activation in PMA-differentiated human THP1 cells assessed as reduction in LPS-stimulated IL-1beta secretion incubated for 1 hr prior to stimulation with nigericin for 1 hr by quanti-blue based SEAP repor2018Bioorganic & medicinal chemistry, 07-30, Volume: 26, Issue:13
Synthesis of 1,5-Anhydro-d-fructose derivatives and evaluation of their inflammasome inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (32)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (3.13)18.7374
1990's0 (0.00)18.2507
2000's7 (21.88)29.6817
2010's16 (50.00)24.3611
2020's8 (25.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.27

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.27 (24.57)
Research Supply Index3.53 (2.92)
Research Growth Index4.80 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.27)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (9.09%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other30 (90.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]